Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE trial of neoadjuvant camrelizumab combined with chemotherapy for resectable thoracic esophageal squamous cell carcinoma with multiple lymph-node station metastases
ChiCTR1900026240Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Primary endpoint: Pathologic complete response rate. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900026240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026240.